VC-backed Dicerna Pharmaceuticals sets pricing terms for IPO

According to Fortune, Dicerna Pharmaceuticals has priced its IPO of 5 million shares at between $11 and $13 per share. The stock will trade on the NASDAQ under the ticker symbol “DRNA.” Jefferies, Leerink Swann and Stifel are acting as lead underwriters. Based in Watertown, Mass., Dicerna Pharmaceuticals is a developer of RNA interference-based therapeutics. Its backers include Domain Associates, Skyline Ventures, Deerfield Management, RA Capital, Abingworth Management, Brookside Capital, S.R. One Ltd. and Oxford Bioscience Partners.

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.